Clinical Trials Logo

Filter by:
NCT ID: NCT03462719 Active, not recruiting - Clinical trials for Leukemia, Lymphocytic, Chronic, B-Cell

A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

GLOW
Start date: April 17, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess progression-free survival (PFS) from treatment with ibrutinib plus venetoclax (I+VEN) compared with obinutuzumab plus chlorambucil (G-Clb) as assessed by an Independent Review Committee (IRC).

NCT ID: NCT03462381 Completed - Exercise Clinical Trials

Protein Supplementation and Endurance Exercise Adaptations

Start date: August 1, 2017
Phase: N/A
Study type: Interventional

Participants will perform three endurance training sessions weekly for 12 weeks. All participants will be randomly assigned to the protein supplementation group or the placebo (iso-caloric carbohydrate) group. During the 12 weeks endurance training program participants allocated to the protein group (30 g protein per beverage) will receive a protein drink after exercise and prior to sleep at night on training days. On non-training days participants will only receive a protein drink before sleep. Participants allocated to the carbohydrate group (30 g carbohydrates) will receive a carbohydrate drink instead of a protein drink.

NCT ID: NCT03462134 Completed - Meniscus Lesion Clinical Trials

Predicting the Outcome After Treatment of Meniscal Tears

Start date: January 1, 2018
Phase:
Study type: Observational

In this study the investigators examined the ability of orthopaedic surgeons to predict the outcome of surgery and non-operative treatment in patients (age 45 to 70) with a non-obstructive meniscal tear.

NCT ID: NCT03461302 Recruiting - Atopic Dermatitis Clinical Trials

Efficacy of Topical Coal Tar in Children With Atopic Dermatitis

Start date: February 1, 2018
Phase: Phase 4
Study type: Interventional

Rationale/hypothesis: Atopic dermatitis (AD) is an inflammatory skin disease, occurring most frequently in children. Currently, topically applied corticosteroids are used as a standard anti-inflammatory treatment. When a corticosteroid with a high potency is used for a long period of time, adverse effects like skin atrophy and systemic effects may occur, especially in children. In addition, corticophobia among patients is an issue that warrants alternatives for the treatment of AD in children. An alternative treatment is the topical application of coal tar, which is known to be an effective and safe treatment for AD for ages, and is used in our department for decennia. Although there is convincing evidence in the literature on the safety of coal tar, evidence in the literature on the efficacy of coal tar in the treatment of AD is lacking, especially in children. Objective: To evaluate efficacy of topical treatment with coal tar compared to topical treatment with corticosteroids in children aged 1 to <16 years with moderate to severe AD Study design: investigator-initiated, parallel-group randomized controlled pilot study Study population: Children aged 1 to <16 years with moderate-severe AD Intervention: Patients will be randomized in two groups: (1) topical treatment with coal tar or (2) topical treatment with moderate potency corticosteroids for a treatment duration of 4 weeks. Main study parameters/endpoints: The primary outcome is the percentage change in EASI score at week 2.

NCT ID: NCT03460938 Completed - Myocardial Ischemia Clinical Trials

Remote Ischemic Preconditioning and Postoperative Myocardial Ischemia

MICOLON2
Start date: March 8, 2017
Phase: N/A
Study type: Interventional

High-risk abdominal surgery is frequently complicated by postoperative complications, such as sepsis, pneumonia or anastomotic dehiscence. Asymptomatic myocardial injury after abdominal surgery (MINS) predicts non-cardiac complications. The etiology of MINS in abdominal surgery patients is unknown. Remote ischemic preconditioning (RIPC) is a physiologic mechanism that exposes tissues to brief periods of non-lethal ischemia and reperfusion, creating resistence for future serious ischemic insults. RIPC in patients after cardiac or aortic surgery is associated with a protective effect on the heart. The effect of RIPC in abdominal surgery patients is unknown. Objective of the study: To determine the effect of RIPC on MINS in patients after pancreatic sugery. Study design: Randomised controlled parallel group mono-center pilot study. Study population: 90 adult patients scheduled for elective pancreaticoduodenectomy in St. Antonius Hospital (45 in the intervention group and 45 in the control group). Intervention: RIPC: 3 periods of 5 minutes of ischemia followed by 5 minutes of reperfusion are created by inflating a blood pressure cuff on the upper extremity after induction of anesthesia and prior to surgery. In the control group a non-inflated blood pressure cuff is placed on the upper extremity for 30 minutes. Primary study parameters/outcome of the study: Maximum postoperative concentration of high-sensitive cardiac troponin T. Secondary study parameters/outcome of the study: Markers of inflammatory, intestinal and renal injury, postoperative complications during 30 days, length of stay and hospital mortality.

NCT ID: NCT03459638 Completed - Clinical trials for Cardiovascular Diseases

Periodontitis as Signal for an Underlying Disease

PACMEL
Start date: March 9, 2018
Phase:
Study type: Observational [Patient Registry]

This study investigates the differences between subjects with and without periodontitis in: the prevalence of (pre)diabetes mellitus, the risk of atherosclerotic cardiovascular disease, the prevalence of metabolic syndrome and the risk of obstructive sleep apnea syndrome.

NCT ID: NCT03459443 Terminated - C3 Glomerulopathy Clinical Trials

A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471

Start date: June 20, 2018
Phase: Phase 2
Study type: Interventional

The primary purpose of this study was to evaluate the efficacy of 12 months of oral ACH-0144471 (also known as danicopan and ALXN2040) in participants with C3G or IC-MPGN based on histologic scoring and proteinuria.

NCT ID: NCT03458559 Active, not recruiting - Clinical trials for Prostate Cancer Metastatic to Bone

Rhenium-188-HEDP vs. Radium-223-chloride in Patients With Advanced Prostate Cancer Refractory to Hormonal Therapy

RaRe
Start date: May 16, 2018
Phase: Phase 3
Study type: Interventional

Radium-223 chloride is an alpha-emitting radiopharmaceutical with proven survival benefit in patients with castration-resistant prostate cancer metastatic to bone. Beta-emitting radiopharmaceuticals have proven efficacy for palliating malignant bone pain. Nowadays, rhenium-188-HEDP is used in clinical practice for pain relief and palliative care. Several studies suggest that also rhenium-188-HEDP has the potential to improve overall survival. The purpose of this study is to investigate if treatment with rhenium-188-HEDP results in improvement of overall survival compared to treatment with radium-223-chloride.

NCT ID: NCT03458221 Recruiting - Clinical trials for Recurrent Ovarian Cancer

Signal TrAnsduction Pathway Activity Analysis in OVarian cancER

STAPOVER
Start date: January 31, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this prospective, parallel-group, cohort study is to implement phenotype-guided targeted therapy based on functional signal transduction pathway (STP) activity in recurrent ovarian cancer patients using a novel mRNA-based assay. Existing targeted drugs with tolerable toxicity profiles are used to investigate the therapeutic value beyond their approved indication, which are deemed beneficial in the select group of patients with a relevant predominantly active functional STP, in order to improve survival and maintain quality of life.

NCT ID: NCT03457506 Completed - Breast Cancer Clinical Trials

Intra-individual Comparison of Conventional and Digital PET/CT Scanners

Start date: January 8, 2018
Phase: N/A
Study type: Interventional

In this study, the investigators will analyze the impact of digital PET/CT on the final diagnostic conclusion of the scan in patients with lung cancer, breast cancer, esophageal cancer and a group of mescellaneous cancers.